Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
12.31 USD -3.53% Intraday chart for Viridian Therapeutics, Inc. +1.07% -43.48%
06-11 Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
06-11 Sector Update: Health Care MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MT
Sector Update: Health Care
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins
MT
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket
MT
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-To-Severe Thyroid Eye Disease
CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000
MT
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000
MT
Viridian Therapeutics, Inc. Provides Key Updates on its Anti-Insulin-Like Growth Factor 1 Receptor (IGF-1R) Programs in Thyroid Eye Disease and its Programs Targeting FcRn
CI
Viridian Therapeutics Q3 Loss Widens, Revenue Drops
MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q3 Revenue $72,000
MT
Ypsomed to Customize, Supply Autoinjector Pen Device for Viridian Therapeutics
MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q2 Revenue $72,000
MT
Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease
CI
Viridian Therapeutics Q1 Loss Widens, Revenue Declines
MT
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. News Viridian Therapeutics, Inc.
  5. Highlights